{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:12:03Z","timestamp":1771953123339,"version":"3.50.1"},"reference-count":30,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Measurable residual disease (MRD) monitoring for mutated NPM1 is increasingly used to guide treatment decisions in patients with acute myeloid leukemia (AML) carrying this mutation. NPM1-MRD positivity after induction has been shown to identify patients who may benefit from allogeneic hematopoietic cell transplantation (allo-HCT), and NPM1-MRD monitoring after allo-HCT can detect early relapse, enabling the prompt initiation of salvage therapy. However, recommendations for clinical decision-making based on peritransplant NPM1-MRD levels are missing. In this study, we retrospectively analyzed 172 patients with NPM1-mutant AML treated at 2 German centers to explore the predictive values of NPM1-MRD measured before and after allo-HCT. We found that pretransplant MRD negativity was a strong predictor of favorable long-term overall survival (OS). In contrast, patients with positive and negative NPM1-MRD status at day 30 after HCT showed comparable OS. Finally, statistically derived NPM1-MRD thresholds effectively stratified MRD-high and MRD-low patient groups with differential outcome, with 2 peritransplant MRD risk scores obtained by longitudinal integration. First, a combined score using MRD measurements before HCT and at day 30 HCT was used to guide early reduction of immunosuppression (concordance index [C-index], 0.737). Second, a combined score using MRD measurements before HCT and at day 30 and day 100 after HCT was used to guide later post-HCT interventions (C-index, 0.841; stratified 2-year OS groups, 100%, 90.1%, 57.1%, and 25.7%; P&amp;lt; .0001). This approach predicted OS better than age, FLT3-ITD status, or morphological remission status. We propose that in the peritransplant setting, NPM1-MRD thresholds are superior to conventional MRD analysis based on binary or log-step change data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017908","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T18:02:28Z","timestamp":1764093748000},"page":"1082-1093","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Predictive capacity of peritransplant measurable residual disease thresholds in\n                    <i>NPM1<\/i>\n                    -mutant acute myeloid leukemia"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7000-4427","authenticated-orcid":false,"given":"Jan Christian","family":"Schroeder","sequence":"first","affiliation":[{"name":"1Department for Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4709-3956","authenticated-orcid":false,"given":"Friederike","family":"Schwartz","sequence":"additional","affiliation":[{"name":"1Department for Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1607-0160","authenticated-orcid":false,"given":"Judith","family":"Metzdorf","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Stem Cell Transplantation, West German Cancer Center Essen, University Hospital Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Barensteiner","sequence":"additional","affiliation":[{"name":"1Department for Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5707-7840","authenticated-orcid":false,"given":"Lucas","family":"Mix","sequence":"additional","affiliation":[{"name":"1Department for Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6595-7775","authenticated-orcid":false,"given":"Lisa-Marie","family":"Necke","sequence":"additional","affiliation":[{"name":"1Department for Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Fehn","sequence":"additional","affiliation":[{"name":"1Department for Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Riedel","sequence":"additional","affiliation":[{"name":"1Department for Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liv","family":"Jentzsch","sequence":"additional","affiliation":[{"name":"1Department for Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0025-0057","authenticated-orcid":false,"given":"Philipp","family":"Faustmann","sequence":"additional","affiliation":[{"name":"1Department for Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wichard","family":"Vogel","sequence":"additional","affiliation":[{"name":"1Department for Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6052-2618","authenticated-orcid":false,"given":"Wolfgang Andreas","family":"Bethge","sequence":"additional","affiliation":[{"name":"1Department for Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Schroeder","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Stem Cell Transplantation, West German Cancer Center Essen, University Hospital Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-2805","authenticated-orcid":false,"given":"Claudia","family":"Lengerke","sequence":"additional","affiliation":[{"name":"1Department for Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"3German Cancer Consortium, Partner Site T\u00fcbingen, a partnership between DKFZ and University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"12","key":"2026022411385680500_bib1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2026022411385680500_bib2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/MOH.0000000000000482","article-title":"Which patients with acute myeloid leukemia in CR1 can be spared an allogeneic transplant?","volume":"26","author":"Craddock","year":"2019","journal-title":"Curr Opin Hematol"},{"issue":"12","key":"2026022411385680500_bib3","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"issue":"19","key":"2026022411385680500_bib4","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.2023023096","article-title":"Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2026022411385680500_bib5","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"2026022411385680500_bib6","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","article-title":"Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian Acute Myeloid Leukemia Study Group","volume":"29","author":"Kr\u00f6nke","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026022411385680500_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","article-title":"Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the acute Leukemia French Association Group","volume":"35","author":"Balsat","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15","key":"2026022411385680500_bib8","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.18632\/oncotarget.2196","article-title":"MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin","volume":"5","author":"Lambert","year":"2014","journal-title":"Oncotarget"},{"issue":"8","key":"2026022411385680500_bib9","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2014.104133","article-title":"Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse","volume":"99","author":"Hubmann","year":"2014","journal-title":"Haematologica"},{"issue":"6","key":"2026022411385680500_bib10","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/sj.leu.2404149","article-title":"Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations","volume":"20","author":"Gorello","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"2026022411385680500_bib11","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.leu.2404637","article-title":"Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations","volume":"21","author":"Chou","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"2026022411385680500_bib12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2012-10-461749","article-title":"The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML","volume":"122","author":"Shayegi","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2026022411385680500_bib13","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.21873\/anticanres.11130","article-title":"Pre-transplant quantitative determination of NPM1 mutation significantly predicts outcome of ailogeneic hematopoietic stem cell transplantation in patients with normal karyotype AML in complete remission","volume":"36","author":"Karas","year":"2016","journal-title":"Anticancer Res"},{"issue":"9","key":"2026022411385680500_bib14","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood.2019002959","article-title":"Molecular MRD status and outcome after transplantation in NPM1-mutated AML","volume":"135","author":"Dillon","year":"2020","journal-title":"Blood"},{"issue":"10","key":"2026022411385680500_bib15","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s00277-018-3373-y","article-title":"Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients","volume":"97","author":"Bill","year":"2018","journal-title":"Ann Hematol"},{"issue":"7","key":"2026022411385680500_bib16","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1038\/bcj.2016.46","article-title":"Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia","volume":"6","author":"Kayser","year":"2016","journal-title":"Blood Cancer J"},{"issue":"2","key":"2026022411385680500_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ajh.25355","article-title":"Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission","volume":"94","author":"Poir\u00e9","year":"2019","journal-title":"Am J Hematol"},{"issue":"2","key":"2026022411385680500_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41409-024-02465-2","article-title":"Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia","volume":"60","author":"Christopher","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"2026022411385680500_bib19","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"26","key":"2026022411385680500_bib20","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2026022411385680500_bib21","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/bloodadvances.2024014767","article-title":"Pre-transplant MRD does not seem to impact survival in NPM1-mutated AML undergoing allogeneic stem cell transplantation","volume":"9","author":"Fraccaroli","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"2026022411385680500_bib22","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1002\/hem3.55","article-title":"Quantifying NPM1 MRD in AML patients prior to allogeneic stem cell transplantation: where to draw the line?","volume":"8","author":"Schwind","year":"2024","journal-title":"HemaSphere"},{"issue":"2","key":"2026022411385680500_bib23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/10428194.2018.1485910","article-title":"Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML","volume":"60","author":"Delsing Malmberg","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2026022411385680500_bib24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.exphem.2008.09.014","article-title":"Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation","volume":"37","author":"Bacher","year":"2009","journal-title":"Exp Hematol"},{"issue":"8","key":"2026022411385680500_bib25","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.bbmt.2018.04.017","article-title":"Deep NPM1 sequencing following allogeneic hematopoietic cell transplantation improves risk assessment in adults with NPM1-mutated AML","volume":"24","author":"Zhou","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"2026022411385680500_bib26","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2009-03-213389","article-title":"Minimal residual disease levels assessed by NPM1 mutation\u2013specific RQ-PCR provide important prognostic information in AML","volume":"114","author":"Schnittger","year":"2009","journal-title":"Blood"},{"key":"2026022411385680500_bib27","author":"R Core Team","year":"2022"},{"key":"2026022411385680500_bib28","author":"RStudio Team","year":"2020"},{"issue":"26","key":"2026022411385680500_bib29","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood.2020005998","article-title":"Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial","volume":"136","author":"Kapp-Schwoerer","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2026022411385680500_bib30","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1082\/2503298\/blooda_adv-2025-017908-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1082\/2503298\/blooda_adv-2025-017908-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:39:08Z","timestamp":1771951148000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/4\/1082\/548460\/Predictive-capacity-of-peritransplant-measurable"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017908","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,24]]},"published":{"date-parts":[[2026,2,12]]}}}